Yasser Ousman, MD
Endocrinology, Diabetes & Metabolism · Fairfax, VANPI 1801845284
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $43,219 of the $53,121 with a category attached, or 81.4%. Sanofi-aventis U.S. LLC accounts for 97.4% of it on its own, with 21 other manufacturers making up the rest. Reporting peaked in 2019 at $19,072 and has fallen 96.8% since, to $613 in 2025. Among endocrinology, diabetes & metabolism clinicians in VA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 124 payments — averaging $428.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi-aventis U.S. LLC$52K
- Novo Nordisk$440
- Lilly USA, LLC$168
- Xeris Pharmaceuticals, Inc.$127
- Tandem Diabetes Care, Inc.$116
- Abbott$89
- plus $420 from 16 others
What the payments were for
- Consulting fees$4,8809%
- Speaking & faculty fees$43,21981%
- Travel & lodging$6701%
- Food & beverage$4,3218%
- Education$320%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi-aventis U.S. LLC | 79 | $51,761 |
| Novo Nordisk | 12 | $440 |
| Lilly USA, LLC | 7 | $168 |
| Xeris Pharmaceuticals, Inc. | 2 | $127 |
| Tandem Diabetes Care, Inc. | 1 | $116 |
| Abbott | 4 | $89 |
| Bayer | 2 | $55 |
| AbbVie | 2 | $49 |
| Ascendis Pharma Endocrinology Inc | 2 | $38 |
| Averitas Pharma Inc. | 1 | $27 |
| Valeritas, Inc. | 1 | $25 |
| Sequel Med Tech, LLC | 1 | $25 |
| Corcept Therapeutics | 1 | $24 |
| Antares Pharma, Inc. | 1 | $24 |
| AstraZeneca | 1 | $24 |
| Boehringer Ingelheim | 1 | $21 |
| Rhythm Pharmaceuticals, Inc. | 1 | $20 |
| Madrigal Pharmaceuticals | 1 | $20 |
| BETA Bionics, Inc. | 1 | $19 |
| Amneal Pharmaceuticals LLC | 1 | $18 |
| Amgen | 1 | $17 |
| Novartis | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SOLIQUA 100/33$35,701
- TOUJEO$10,140
- DISEASE STATE$1,983
- TZIELD$288
- t:slim X2 insulin pump$116
- RECORLEV$106
How this compares
$53,121 in reported general payments places this provider in the 90th percentile of 223 endocrinology, diabetes & metabolism providers in Virginia.
See all endocrinology, diabetes & metabolism providers in Virginia →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 274 | $348,469 |
| OzempicSemaglutide | 174 | $218,915 |
| TrulicityDulaglutide | 86 | $146,139 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 130 | $142,044 |
| JardianceEmpagliflozin | 73 | $92,314 |
| Tresiba Flextouch U-200Insulin Degludec | 57 | $59,988 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 52 | $56,050 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 54 | $26,080 |
| XyostedTestosterone Enanthate | 13 | $20,846 |
| Novolog FlexpenInsulin Aspart | 75 | $17,880 |
| ProliaDenosumab | 11 | $17,861 |
| Humalog Kwikpen U-200Insulin Lispro | 11 | $17,336 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 30 | $16,223 |
| Cinacalcet Hcl | 28 | $12,466 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 13 | $11,916 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity, Insulin Lispro | $168 | $495,237376 claims |
| Novo NordiskOzempic, Rybelsus, Novolog | $440 | $235,663199 claims |
| Boehringer IngelheimJardiance, Tradjenta | $21 | $100,37589 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33, Lantus | $51,761 | $59,51771 claims |
| Antares Pharma, Inc.Xyosted | $24 | $20,84613 claims |
| AmgenProlia | $17 | $17,86111 claims |
| AbbVieSynthroid | $49 | $8,710122 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $18 | $2,860356 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 223 endocrinology, diabetes & metabolism providers in Virginia.
Other endocrinology, diabetes & metabolism in Fairfax
- Samim EnayatFairfax$217K
- Denise ArmelliniFairfax$152K
- Roy LangleyFairfax$5K
- Farhad ZangenehSterling$1.2M
- James MulindaRoanoke$788K
- Jeffrey SicatGlen Allen$657K
- Dewey BaileyRoanoke$645K
- Domenica RubinoArlington$608K
- Samamtha HudsonMidlothian$372K
- Elias SirajNorfolk$316K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.